Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven M. Hersch, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Steven Hersch and Herminia Rosas.
Connection Strength

7.298
  1. Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. Neuroimage Clin. 2018; 20:236-242.
    View in: PubMed
    Score: 0.749
  2. A systems-level "misunderstanding": the plasma metabolome in Huntington's disease. Ann Clin Transl Neurol. 2015 Jul; 2(7):756-68.
    View in: PubMed
    Score: 0.619
  3. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology. 2014 Mar 11; 82(10):850-7.
    View in: PubMed
    Score: 0.566
  4. Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol. 2012 Jul; 69(7):887-93.
    View in: PubMed
    Score: 0.506
  5. A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Mov Disord. 2011 Aug 01; 26(9):1691-7.
    View in: PubMed
    Score: 0.469
  6. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage. 2010 Feb 15; 49(4):2995-3004.
    View in: PubMed
    Score: 0.420
  7. Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease? Ann N Y Acad Sci. 2008 Dec; 1147:196-205.
    View in: PubMed
    Score: 0.395
  8. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics. 2008 Apr; 5(2):226-36.
    View in: PubMed
    Score: 0.377
  9. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008 Apr; 131(Pt 4):1057-68.
    View in: PubMed
    Score: 0.376
  10. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 2006 Jan 24; 66(2):250-2.
    View in: PubMed
    Score: 0.324
  11. Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx. 2004 Apr; 1(2):263-72.
    View in: PubMed
    Score: 0.286
  12. 10 most commonly asked questions about Huntington's disease. Neurologist. 2001 Nov; 7(6):364-8.
    View in: PubMed
    Score: 0.242
  13. Neuroprotective therapy for Huntington's disease: new prospects and challenges. Expert Rev Neurother. 2001 Sep; 1(1):111-8.
    View in: PubMed
    Score: 0.239
  14. Impaired Cerebrovascular Reactivity in Huntington's Disease. Front Physiol. 2021; 12:663898.
    View in: PubMed
    Score: 0.237
  15. Association of Dilated Perivascular Spaces and Disease Severity in Patients With Huntington Disease. Neurology. 2021 02 09; 96(6):e890-e894.
    View in: PubMed
    Score: 0.225
  16. Electrocardiogram Abnormalities Suggest Aberrant Cardiac Conduction in Huntington's Disease. Mov Disord Clin Pract. 2018 May-Jun; 5(3):306-311.
    View in: PubMed
    Score: 0.189
  17. The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology. 2017 Aug 08; 89(6):594-601.
    View in: PubMed
    Score: 0.179
  18. Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease. Mol Neurobiol. 2016 May; 53(4):2132-40.
    View in: PubMed
    Score: 0.154
  19. Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. PLoS Curr. 2010 Dec 29; 2:RRN1205.
    View in: PubMed
    Score: 0.114
  20. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006 Sep; 21(9):1317-25.
    View in: PubMed
    Score: 0.085
  21. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 2002 Mar 12; 58(5):695-701.
    View in: PubMed
    Score: 0.062
  22. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16; 9(11).
    View in: PubMed
    Score: 0.057
  23. HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology. 2013 Sep 24; 81(13):1134-40.
    View in: PubMed
    Score: 0.034
  24. Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics. 2013 Nov; 14(3-4):173-9.
    View in: PubMed
    Score: 0.034
  25. A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. Anal Biochem. 2013 May 15; 436(2):112-20.
    View in: PubMed
    Score: 0.033
  26. Population stratification may bias analysis of PGC-1a as a modifier of age at Huntington disease motor onset. Hum Genet. 2012 Dec; 131(12):1833-40.
    View in: PubMed
    Score: 0.032
  27. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem Biophys Res Commun. 2012 Aug 03; 424(3):404-8.
    View in: PubMed
    Score: 0.032
  28. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. Am J Hum Genet. 2012 Mar 09; 90(3):434-44.
    View in: PubMed
    Score: 0.031
  29. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 2012 Mar 06; 78(10):690-5.
    View in: PubMed
    Score: 0.031
  30. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A. 2011 Oct 11; 108(41):17141-6.
    View in: PubMed
    Score: 0.030
  31. Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. Anal Biochem. 2011 Mar 15; 410(2):304-6.
    View in: PubMed
    Score: 0.028
  32. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim Biophys Acta. 2010 Jul-Aug; 1802(7-8):673-81.
    View in: PubMed
    Score: 0.027
  33. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal Biochem. 2009 Dec 01; 395(1):8-15.
    View in: PubMed
    Score: 0.026
  34. Repeat instability in the 27-39 CAG range of the HD gene in the Venezuelan kindreds: Counseling implications. Am J Med Genet B Neuropsychiatr Genet. 2009 Apr 05; 150B(3):425-9.
    View in: PubMed
    Score: 0.025
  35. Linking SNPs to CAG repeat length in Huntington's disease patients. Nat Methods. 2008 Nov; 5(11):951-3.
    View in: PubMed
    Score: 0.024
  36. The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005 Nov; 108(2):193-207.
    View in: PubMed
    Score: 0.020
  37. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci U S A. 2005 Aug 02; 102(31):11023-8.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.